101 related articles for article (PubMed ID: 23075235)
1. The changing face of tumor phenotypes.
Macfarlane R; Sauter ER
Biomark Med; 2012 Oct; 6(5):563-6. PubMed ID: 23075235
[No Abstract] [Full Text] [Related]
2. Cancer stem cells and markers: new model of tumorigenesis with therapeutic implications.
Natarajan TG; Ganesan N; Fitzgerald KT
Cancer Biomark; 2010; 9(1-6):65-99. PubMed ID: 22112470
[TBL] [Abstract][Full Text] [Related]
3. Cancer epigenetics as biomarkers of clinical significance.
Panayiotidis MI
Cancer Lett; 2014 Jan; 342(2):168-9. PubMed ID: 24183850
[No Abstract] [Full Text] [Related]
4. [Novel tumor markers-circulating miRNA].
Xie L; Qian XP; Liu BR
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):641-2. PubMed ID: 22340041
[No Abstract] [Full Text] [Related]
5. Carcinoembryonic antigen and cytokeratin 20 in peritoneal cells of cancer patients: are we aware of what we are detecting by mRNA examination?
Kowalewska M; Chechlinska M; Nowak R
Br J Cancer; 2008 Jan; 98(2):512-3; author reply 514. PubMed ID: 18195708
[No Abstract] [Full Text] [Related]
6. Cancer genomics: the unknown unknowns.
Lotze MT; Yu Y
Curr Opin Investig Drugs; 2006 Jun; 7(6):497-500. PubMed ID: 16784019
[No Abstract] [Full Text] [Related]
7. Bioregulation.
Pardee AB
J Cell Physiol; 2015 Dec; 230(12):2898-902. PubMed ID: 26031897
[TBL] [Abstract][Full Text] [Related]
8. [Regulation and manifestations of apoptosis in normal tissues and in neoplasms].
Raĭkhlun NT; Raĭkhlun AN
Vopr Onkol; 2002; 48(2):159-71. PubMed ID: 12227063
[No Abstract] [Full Text] [Related]
9. [Pdcd4 tumor suppressor: properties, functions, and their application to oncology].
Vikhreva PN; Shepelev MV; Korobko EV; Korobko IV
Mol Gen Mikrobiol Virusol; 2010; (2):3-11. PubMed ID: 20545042
[TBL] [Abstract][Full Text] [Related]
10. Efforts aimed at reducing noise, data overload in microarrays.
Tuma RS
J Natl Cancer Inst; 2005 Aug; 97(16):1173-5. PubMed ID: 16106018
[No Abstract] [Full Text] [Related]
11. Molecular heterogeneity of tumor endothelium.
Aird WC
Cell Tissue Res; 2009 Jan; 335(1):271-81. PubMed ID: 18726119
[TBL] [Abstract][Full Text] [Related]
12. Exploring the human genome in cancer with genomic approaches.
Scheel JR; Kuo MD
J Vasc Interv Radiol; 2006 Aug; 17(8):1225-33. PubMed ID: 16923971
[No Abstract] [Full Text] [Related]
13. Cancer stem cells: a step toward the cure.
Boman BM; Wicha MS
J Clin Oncol; 2008 Jun; 26(17):2795-9. PubMed ID: 18539956
[No Abstract] [Full Text] [Related]
14. miRNAs as molecular biomarkers of cancer.
Fabbri M
Expert Rev Mol Diagn; 2010 May; 10(4):435-44. PubMed ID: 20465498
[TBL] [Abstract][Full Text] [Related]
15. Regulation of p53R2 and its role as potential target for cancer therapy.
Wang X; Zhenchuk A; Wiman KG; Albertioni F
Cancer Lett; 2009 Apr; 276(1):1-7. PubMed ID: 18760875
[TBL] [Abstract][Full Text] [Related]
16. Engrailed homeobox transcription factors as potential markers and targets in cancer.
McGrath SE; Michael A; Pandha H; Morgan R
FEBS Lett; 2013 Mar; 587(6):549-54. PubMed ID: 23395604
[TBL] [Abstract][Full Text] [Related]
17. Next generation sequencing applications in cancer research.
Zhang W; Nykter M; Chen K
Cancer Lett; 2013 Nov; 340(2):149-50. PubMed ID: 23764479
[No Abstract] [Full Text] [Related]
18. The HER-2/neu story: from oncogene through prognostic marker to therapeutic strategy determinant and monoclonal therapy.
Mehigan BJ; Kerin MJ
Eur J Surg Oncol; 1999 Apr; 25(2):111-2. PubMed ID: 10218450
[No Abstract] [Full Text] [Related]
19. Medicine: profile of a tumour.
Kallioniemi O
Nature; 2004 Mar; 428(6981):379-82. PubMed ID: 15042074
[No Abstract] [Full Text] [Related]
20. Tumor vascular biomarkers: new opportunities for cancer diagnostics.
Li C; Sasaroli D; Chen X; Hu J; Sandaltzopoulos R; Omidi Y; Coukos G
Cancer Biomark; 2010-2011; 8(4-5):253-71. PubMed ID: 22045357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
